Massive pulmonary embolism in diabetic ketoacidosis and non-ketotic hyperosmolar state: case series and review of the literature

References

• Carr ME. Diabetes mellitus - a hypercoagulable state. J Diabetes Complications 2001; 15: 44–54.
   PubMed Web of Science ®Google Scholar
• Hamblin PS, Topliss DJ, Chosich N, et al. Deaths associated with diabetic ketoacidosis and hyperosmolar coma, 1973-1988. Med J Aust 1989; 151: 439–44.
   PubMed Web of Science ®Google Scholar
• Quigley RL, Curran RD, Stagl RD, et al. Management of massive pulmonary thromboembolism complicating diabetic ketoacidosis. Ann Thorac Surg 1994; 57: 1322–4.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Morishita E, Jokaji H, et al. Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes 1996; 45 (Suppl. 3): 109–10.
   Google Scholar
• El Khawand C, Jamart J, Donckier J, et al. Hemostasis variables in type 1 diabetic patients without demonstrable vascular complications. Diabetes Care 1993; 16: 1137–45.
   PubMed Web of Science ®Google Scholar
• Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41 (Suppl. 2): 32–5.
   Google Scholar
• Garcia Frade q, de la Calle H, Alava I, et al. Diabetes mellitus as a hypercoagulable state and its relationship with fibrin fragments and vascular damage. Thromb Res 1987; 47: 533–40.
   PubMed Web of Science ®Google Scholar
• Small M, Douglas JT, Lowe GD, et al. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus. Haemostasis 1986; 16: 417–23.
   PubMedGoogle Scholar
• Hughes A, McVerry BA, Wilkinson L, et al. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983; 69: 254–9.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Frank HJ, Harwig SS. Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care 1984; 7: 174–9.
   Google Scholar
• Borsey DQ Prowse CV, Gray RS, et al. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol 1984; 37: 659–64.
   PubMed Web of Science ®Google Scholar
• Collier A, Rumley A, Rumley AG, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41: 909–13.
   PubMed Web of Science ®Google Scholar
• Patrassi GM, Picchinenna R, Vettor R, et al. Antithrombin III activity and concentration in diabetes mellitus. Thromb Haemostasis 1985; 54: 415–17.
   PubMed Web of Science ®Google Scholar
• Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643–54.
   PubMed Web of Science ®Google Scholar
• Khechai F, Ollivier V, Bridey F, et al. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol 1997; 17: 2885–90.
   PubMed Web of Science ®Google Scholar
• Reverter JL, Reverter JC, Tassies D, et al. Thrombo-modulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997; 56: 93–9.
   PubMed Web of Science ®Google Scholar
• Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health 1993; 24 (Suppl. 1): 263–6.
   Google Scholar
• Adelstein S, Gomperts ED, Joffe BI, et al. Haemostatic factors in black and white diabetics. S Afr Med J 1979; 55: 325–8.
   PubMed Web of Science ®Google Scholar
• Lopez Y, Paloma MJ, Rifon J, et al. Measurement of prothrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999; 93: 71–8.
   PubMed Web of Science ®Google Scholar
• Murakami T, Komiyama Y, Egawa H, et al. Elevation of factor XIa-alpha 1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy. Diabetes 1993; 42: 233–8.
   PubMed Web of Science ®Google Scholar
• Nagai T. Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy. J Atheroscler Thromb 1994; 1: 37–40.
   PubMedGoogle Scholar
• Yokoyama H, Myrup B, Rossing P, et al. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996; 19: 441–5.
   PubMed Web of Science ®Google Scholar
• Davi G, Gennaro F, Spatola A, et al. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications 1992; 6: 7–11.
   PubMedGoogle Scholar
• Mirshahi M, Soria J, Soria C, et al. Glycosylation of human fibrinogen and fibrin in vitro its consequences on the properties of fibrin(ogen). Thromb Res 1987; 48: 279–89.
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983; 32: 680–4.
   Google Scholar
• Carr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution digestion of plasma clots. Blood Coagul Fibrinolysis 1995; 6: 567–73.
   PubMed Web of Science ®Google Scholar
• Geiger M, Binder BR. Plasminogen activation in diabetes mellitus. Enzyme 1988; 40: 149–57.
   PubMedGoogle Scholar
• Juhan-Vague I, Roul C, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemostat 1989; 61: 370–3.
   Google Scholar
• Gough SCL, Rice PJS, Chapman C, et al. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993; 10: 638–42.
   PubMed Web of Science ®Google Scholar
• Cerelio A, Quataro A, DelloRusso P, et al. Protein C deficiency in insulin dependent diabetes: a hyperglycemia related phenomenon. Thromb Haemost 1990; 65: 104–7.
   Google Scholar
• Buyukasik Y, Ileri NS, Haznedaroglu IC, et al. Enhanced subclinical coagulation activation during diabetic ketoacidosis. Diabetes Care 1998; 21: 868–70.
   PubMed Web of Science ®Google Scholar
• Ileri NS, Buyukaisk Y, Karaahmetoglu S, et al. Evaluation of the hemostatic system during ketoacidotic deterioration of diabetes mellitus. Haemostasis 1999; 29: 318–25.
   PubMedGoogle Scholar
• Wallace JM, Rao AV, Glassroth J, et al. Respiratory illness in persons with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1523–9.
   PubMed Web of Science ®Google Scholar
• Wood KE. Major pulmonary embolism: review of pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877–905.
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Rietti P. Chirico MA. Cardiac arrest in acute pulmonary embolism: a clinico-pathological study. G Hal Cardiol 1994; 24: 21–6.
   Google Scholar
• Borst RH. First results of emergency treatment in massive fulminant lung embolism by means of a rapidly injected streptokinase in a high initial dose. Anaesthetist 1980; 29: 39–45.
   PubMed Web of Science ®Google Scholar
• Bailen MR, Cuadra JAR, Hoyos EA, et al. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: a review. Crit Care Med 2001; 29: 2211–18.
   PubMed Web of Science ®Google Scholar